Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: AI generated image
The hantavirus outbreak may no longer be confined to the luxury Dutch cruise ship MV Hondius, with health officials now assessing the possibility of wider exposure. Officials at the US Centers for Disease Control and Prevention (CDC) said that although no cases have been reported in the US so far, the agency is monitoring 41 people for possible exposure.
The 41 includes the 18 people evacuated from the hantavirus-hit ship from Spain’s Canary Islands.
Notably, of the 18 passengers evacuated, two were carried in the plane's biocontainment units out of an abundance of caution — one who tested positive and another considered a suspected case. They were quarantined at a special facility in Nebraska. The remaining 16 are being quarantined in Omaha and Atlanta.
Speaking to CNN from a biocontainment unit at the University of Nebraska Medical Center in Omaha, Dr. Stephen Kornfeld of Oregon said he “feels wonderful” and is not experiencing symptoms.
Spanish officials confirmed that after initially testing positive for hantavirus, Dr. Kornfeld has since tested negative twice for the disease, meaning no Americans currently have the illness, Forbes reported.
CDC Monitoring More People
However, an additional 16 people are being monitored by the CDC.
The new individuals were not on the cruise ship but were passengers on an April 25 flight to Johannesburg and were exposed to someone known to have been infected, said Dr. David Fitter, who is leading the CDC response to the outbreak, according to The New York Times.
Also read: Shocking Study Finds Andes Hantavirus Could Linger In Semen For Years, Pose Transmission Risk
Seven other passengers from the cruise ship had disembarked on April 24 in St. Helena, an island in the Atlantic Ocean, returned to the US on commercial flights, and are being monitored by state health departments.
As of May 14, there were no confirmed hantavirus cases in the United States, Dr. Fitter said.
“Our job is to ensure that we are monitoring and in contact with anybody that might have been on the flight this person had taken,” Dr. Fitter told reporters. The agency is “monitoring all Americans that potentially would have been exposed, whether in the US or abroad, and we have been in contact with them,” he said.
According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.
A Dutch couple is believed to have first been exposed to the virus while visiting a birdwatching site in Argentina.
The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.
While all passengers onboard the cruise have been taken care of by health authorities, the virus’ long incubation period remains a serious concern. This means that even asymptomatic individuals could potentially become infectious 6-8 weeks later.
The WHO recommends that people exposed to hantavirus should be:
Credit: iStock
The UK is witnessing yet another outbreak of meningitis, with one college student dead and two others infected in Berkshire, according to the UK Health Security Agency (UKHSA).
According to the agency, close contacts of those affected are being offered antibiotics as a precautionary measure.
Also Read: Why Rebranding PCOS As PMOS Could Mark A New Era In Women’s Health
While stressing that the risk to the wider public remains low, the UKHSA confirmed that one case has been identified as Meningitis B (MenB), while further testing is ongoing.
The latest infections come after a small number of meningitis B cases were reported in the Weymouth region in April, followed by a major outbreak in Kent in March that affected more than 30 people and led to the deaths of a sixth-form pupil and a university student.
The young person who died attended The Henley College, according to a local GP surgery.
Authorities are reportedly sharing information about the infection with students and parents at affected schools. The other two cases are believed to be linked to schools in the Reading area. But the officials are yet to disclose the exact link.
Health officials said close contacts of the infected individuals are being offered antibiotics as a precaution.
Read More: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support
GP surgery, the Hart Surgery, based in Henley-on-Thames, stated that it was in contact with the UKHSA due to the college’s location, adding that the agency was “actively contacting those who may be at risk due to a close association with the student involved.”
However, it said anyone whom the UKHSA has not contacted does not require treatment, and students and staff can continue attending the sixth-form college as usual.
“The number of confirmed cases is very low, so there are currently no plans for a local emergency meningitis vaccination programme,” it added.
Also read: UK Reports Meningitis Outbreak Among School Children: All You Need To Know
Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, known as the meninges. Fever is often considered one of the classic symptoms, although it may not always be present.
Understanding the symptoms, causes, and treatment options is important for early diagnosis and timely medical care.
“Anyone can get meningitis, and around 300 to 400 cases of meningococcal disease are diagnosed in England every year. It is most common in babies, young children, teenagers, and young adults," said Dr Rachel Mearkle, a consultant in health protection at the UKHSA.
“It needs to be treated quickly, so it is important to know the signs and symptoms. They can appear in any order and may not all be present, so seek rapid medical attention if there is ever any concern," she added.
The expert noted that "meningococcal meningitis requires very close contact to spread, and large outbreaks such as the one recently seen in Kent are thankfully rare."
“Meningococcal disease does not spread easily, and the risk to the wider public remains low.”
Health officials urged the public to remain alert to the warning signs of meningococcal meningitis. Common symptoms include:
“If the disease is suspected, immediate medical attention should be sought, as it can progress rapidly,” the officials said. While antibiotics provide the quickest short-term protection, vaccines offer longer-term protection.
Credit: Canva
Pancreatic cancer has long been one of the toughest challenges in oncology. With a five-year survival rate hovering around 13 per cent and recurrence rates approaching 80 per cent after treatment, the odds have historically been stacked against patients.
However, an experimental drug called daraxonrasib, developed by the US-based late-stage clinical oncology company Revolution Medicines, has shown promise in improving survival rates in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Brian M. Wolpin, professor of medicine at Harvard Medical School, and principal investigator for the trial.
Wolpin noted that the study “indicates that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy.”
Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.
Daraxonrasib, described as a multi-selective inhibitor of RAS(ON) proteins, is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.
In the clinical trial, daraxonrasib showed a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.
The drug was generally well tolerated and showed a manageable safety profile, with no new safety concerns identified.
Daraxonrasib works by blocking KRAS signalling proteins that drive tumor growth.
Pancreatic cancer is considered one of the most RAS-addicted cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations.
Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer
The controlled Phase 3 clinical trial evaluated daraxonrasib in patients with previously treated metastatic PDAC.
The trial included patients with pancreatic tumours carrying a wide range of RAS variants, as well as patients without identified RAS mutations.
The results showed that daraxonrasib significantly improved overall survival in patients with previously treated metastatic pancreatic cancer.
Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung, and colon cancers.
“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.
According to the company, “Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”
Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also common.
Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.
Revolution Medicines said it plans to submit the data to global regulators, including the US Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.
The findings are also expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pancreatic cancer typically begins in the ducts of the organ and can rapidly spread from there to the rest of the organ. Early-stage pancreatic tumors do not show up on imaging tests, making this version of the disease difficult to diagnose until it infects other organs.
The prevention and early detection remain vital.
Experts warn that pancreatic cancer often masquerades as common ailments, delaying diagnosis. Here are some early symptoms that should never be ignored:
© 2024 Bennett, Coleman & Company Limited